AzTrials
AzTrials

Psoriatic ArthritisUPtimum-PsANCT05616871

An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

An observational study of Psoriatic Arthritis, run by AbbVie at 89 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis. Upadacitinib (RINVOQ) is approved drug for the treatment of adult participants with active PsA in Europe. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis
How many people
464 participants
Where
89 sitesin 4 countries
Study dates
15 Dec 2022to 11 Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult participants with Psoriatic Arthritis (PsA)

Who may be able to join

  • Confirmed diagnosis of active psoriatic arthritis (PsA) whose peripheral involvement justifies the prescription of upadacitinib upon judgement of the treating physician.
  • Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
  • Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies.
  • Participants able to understand and communicate with the investigator and comply with the requirements of the study.

Who cannot join

  • Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
  • Prior treatment with upadacitinib.

Trial locations and contacts

89 sites in 4 countries.

89 sites in 4 countries

France38 sites

  • CH AIX LES BAIN - Reine Hortense /ID# 252465

    Aix-les-Bains, 73100

  • Duplicate_CHU Amiens-Picardie Site Sud /ID# 252527

    Amiens, Somme, 80054

  • Cabinet Medical Dr Albert-Sabonnadiere - Antibes /ID# 252523

    Antibes, Provence-Alpes-Côte d'Azur Region, 06000

  • Centre Hospitalier d'Arras /ID# 252529

    Arras, 62022

  • CH Henri Duffaut /ID# 252620

    Avignon, Vaucluse, 84902

  • Ch Beauvais /Id# 252464

    Beauvais, Oise, 60021

  • Duplicate_CHU de Besancon - Jean Minjoz /ID# 252537

    Besançon, Doubs, 25030

  • CHU Bordeaux - Hopital Pellegrin /ID# 252532

    Bordeaux, New Aquitaine, 33076

  • Centre Hospitalier de Boulogne Sur Mer /ID# 252467

    Boulogne-sur-Mer, 62200

  • Centre Hospitalier Jean Rougie /ID# 259550

    Cahors, 46005

  • Infirmerie Protestante De Lyon /ID# 252075

    Caluire-et-Cuire, Auvergne-Rhône-Alpes, 69300

  • CH de Cannes - Simone Veil /ID# 252600

    Cannes, 06400

  • Chic Castres-Mazamet /Id# 259557

    Castres, Tarn, 81108

  • CHRU Tours - Hopital Trousseau /ID# 252528

    Chambray-lès-Tours, 37170

  • C. H. Sud Francilien /ID# 254945

    Corbeil-Essonnes, 91106

  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 245194

    Créteil, Paris, 94010

  • Duplicate_CHD Vendée- La Roche-sur-Yon - Les Oudairies /ID# 259549

    La Roche-sur-Yon, Vendee, 85000

  • CH La Rochelle - Hopital Saint Louis /ID# 252534

    La Rochelle, 17019

  • CHU Grenoble - Hopital Michallon /ID# 252601

    La Tronche, Isere, 38700

  • CHU Limoges - Dupuytren 1 /ID# 252432

    Limoges, Franche-Comte, 87042

  • Hopital St Joseph - St Luc (Lyon) /ID# 259561

    Lyon, 69007

  • Clinique de la Sauvegarde /ID# 252533

    Lyon, 69009

  • ELSAN - Clinique du Pont de Chaume /ID# 252602

    Montauban, 82000

  • CHU Montpellier - Hopital Saint Eloi /ID# 252078

    Montpellier, Herault, 34295

  • CH de Narbonne /ID# 252525

    Narbonne, 11100

  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 252536

    Nice, Alpes-Maritimes, 06001

  • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 252530

    Orléans, 45067

  • AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 252526

    Paris, 75010

  • AP-HP - Hopital Saint-Antoine /ID# 252627

    Paris, 75012

  • AP-HP - Hopital Bichat - Claude-Bernard /ID# 252531

    Paris, 75018

  • GH Diaconesses Croix Saint-Simon /ID# 252463

    Paris, 75020

  • Cabinet libéral du Dr PAUPIERE /ID# 252604

    Péronne, Somme, 80200

  • CHU de Rennes - Hospital Sud /ID# 252478

    Rennes, 35203

  • Hôpital Charles-Nicolle /ID# 252603

    Rouen, 76000

  • Cabinet Du Dr Judith Payet Dubourg /Id# 252668

    Saint-Pierre-des-Corps, 97410

  • CHU Toulouse - Hopital Purpan /ID# 252077

    Toulouse, Haute-Garonne, 31059

  • Clinique Médipôle Garonne /ID# 252462

    Toulouse, 31036

  • Duplicate_CH Troyes - Hopital Simone Veil /ID# 252625

    Troyes, Aube, 10000

Other trials in France

Greece20 sites

  • 251 Airforce General Hospital /ID# 248092

    Athens, Attica, 11525

  • Henry Dunnant Hospital Center /ID# 247640

    Athens, Attica, 11526

  • General Hospital of Athens Gennimatas /ID# 247635

    Athens, Attica, 11527

  • General Hospital of Athens Laiko /ID# 247634

    Athens, Attica, 11527

  • General Hospital of Athens Laiko /ID# 258030

    Athens, Attica, 11527

  • Naval Hospital of Athens /ID# 247631

    Athens, 11521

  • KAT Atttica General Hospital /ID# 247641

    Athens, 14561

  • University General Hospital Attikon /ID# 248093

    Chaïdári, Attica, 12462

  • University General Hospital of Heraklion PA.G.N.I /ID# 247632

    Heraklion, Crete, 71500

  • University General Hospital of Ioannina /ID# 251899

    Ioannina, 45500

  • Iaso Thessalias /ID# 255110

    Larissa, Larisa, 41500

  • Reg Gen Univ Hosp Larissa /ID# 247642

    Larissa, 41110

  • General Hospital of Elefsina Thriassio /ID# 251900

    Magoula (Attikis), Attica, 19018

  • Iaso /ID# 247649

    Marousi, Attica, 15123

  • Olympion General Clinic /ID# 247644

    Pátrai, Achaia, 26443

  • General Hospital of Athens Ippokratio /ID# 247633

    Thessaloniki, Attica, 11527

  • Bioclinic Thessaloniki /ID# 247648

    Thessaloniki, 54622

  • Euromedica Blue Cross Gen Clin /ID# 251898

    Thessaloniki, 54636

  • General Hospital of Thessaloniki Hippokrateio /ID# 247643

    Thessaloniki, 54642

  • Euromedica General Clinic /ID# 251897

    Thessaloniki, 54645

Other trials in Greece

Germany19 sites

  • Kupka and Kupka, Altenburg, DE /ID# 254758

    Altenburg, Thuringia, 04600

  • Rheumatologische Schwerpunktpraxis Brandt-Juergens /ID# 258152

    Berlin, 12161

  • Praxis Dr. Silke Zinke /ID# 258037

    Berlin, 13055

  • MVZ Herzogin Elisabeth Hospital /ID# 266740

    Braunschweig, 38114

  • Praxis Dilltal /ID# 254761

    Ehringshausen, 35630

  • MVZ Ambulantes Rheumazentrum Erfurt /ID# 256115

    Erfurt, Thuringia, 99096

  • Universitaetsmedizin Greifswald /ID# 254756

    Greifswald, 17475

  • Private Practice - Dr. Hauke E. Heintz /ID# 254757

    Hamburg, 22391

  • Rheumazentrum Ruhrgebiet /ID# 252939

    Herne, North Rhine-Westphalia, 44649

  • Beyer, Kaiserslautern, DE /ID# 254754

    Kaiserslautern, Rhineland-Palatinate, 67659

  • Dr. Bolze, Ludwigshafen, DE /ID# 254134

    Ludwigshafen, 67069

  • Aurich and Sieburg, Magdeburg /ID# 255504

    Magdeburg, Saxony-Anhalt, 39104

  • RHIO Forschungsinstitut /ID# 254752

    Meerbusch, 40668

  • Prof-med-stud.de /ID# 265965

    Munich, 80935

  • Dr. Murawski /ID# 257911

    Neunkirchen, Saarland, 66538

  • Rheumapraxis Dr. Prothmann /ID# 254759

    Püttlingen, Saarland, 66346

  • Knappschaftsklinikum Saar /ID# 255505

    Püttlingen, 66346

  • Krankenhaus der Barmherzigen Brüder Trier /ID# 254762

    Trier, Rhineland-Palatinate, 54292

  • Krankenhaus St. Josef /ID# 254755

    Wuppertal, 42105

Other trials in Germany

Italy12 sites

  • Azienda Ospedaliero Universitaria delle Marche /ID# 250819

    Ancona, 60126

  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari /ID# 251508

    Bari, 70124

  • Universita degli Studi del Molise /ID# 251176

    Campobasso, 86100

  • IRCCS Ospedale San Raffaele /ID# 251562

    Milan, Milano, 20132

  • Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 251183

    Naples, Napoli, 80138

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 250789

    Palermo, 90127

  • Fondazione IRCCS Policlinico San Matteo /ID# 250747

    Pavia, 27100

  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 250817

    Rome, Roma, 00133

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 250669

    Rome, Roma, 00168

  • IRCCS Istituto Clinico Humanitas /ID# 251275

    Rozzano, Lombardy, 20089

  • Azienda Ospedaliera Universitaria Senese /ID# 251146

    Siena, 53100

  • ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 251544

    Udine, 33100

Other trials in Italy

About this study

Official title: Real-world Effectiveness and Treatment Patterns of Upadacitinib in Monotherapy or Used in Combination With Methotrexate in Active Psoriatic Arthritis Patients

Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis.

Upadacitinib (RINVOQ) is approved drug for the treatment of adult participants with active PsA in Europe. Approximately 450 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 4 countries in Europe: France, Germany, Greece and Italy.

Read more

Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 24 months.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Keywords
Psoriatic Arthritis, PsA, UPA, Upadacitinib, Rinvoq®
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05616871
Study groupRoleWhat they receive
Upadacitinib Alone or In Combination with MethotrexateParticipants will receive upadacitinib alone or in combination with methotrexate as prescribed by their physician according to local label in real- world practice.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving Disease Activity in Psoriatic Arthritis (DAPSA): score <=14

    Disease Activity in Psoriatic Arthritis (DAPSA) score is calculated by the sum of values of rheumatic parameters [tender joint count (TJC/ 68) + swollen joint count (SJC/ 66) + visual analog scale VAS Patient Global Disease Activity (PtGA) in cm + VAS Patient Pain in cm + C Reactive Protein (CRP) in mg/dL].

    Measured: Month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2022
  2. Study start15 Dec 2022
  3. Primary completion11 Jun 2026
  4. Study completion11 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
464 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05616871
Sponsor's protocol ID
P22-897
Acronym
UPtimum-PsA
Status last verified
Jul 2026
First submitted
9 Nov 2022
Last updated
27 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Psoriatic Arthritis, run by AbbVie at 89 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 89 sites in France, Greece, Germany, Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving Disease Activity in Psoriatic Arthritis (DAPSA): score <=14 (time frame: Month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05616871.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in